LIMN (Liminatus Pharma) Dividends Received


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

LIMN
13GF Score
Liminatus Pharma Inc LIMN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price